Inclusion Criteria:

          -  History of Stage 0-III colon or rectal cancer with primary resection 1 year previously

          -  Post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence
             of disease

          -  Must not have cardiovascular risk factors including unstable angina, history of
             myocardial infarction, or cerebrovascular accident, coronary artery bypass surgery, or
             NY Heart Assoc Class III or IV heart failure.

          -  Patients must not have known uncontrolled hyperlipidemia (defined as LDL-C >/= 190
             mg/dL or triglycerides >/= 500 mg/dL within the past 3 years or uncontrolled high
             blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to
             registration

          -  At least 30 days from completion of adjuvant chemo and RT.

          -  Presence of gastroesophageal reflux disease acceptable if controlled with medications

          -  Not receiving or planning to receive concomitant corticosteroids,nonsteroidal
             anti-inflammatory drugs(NSAIDs), nor anticoagulants. Maximum aspirin dose

               -  100 mg per day or ≤ two 325 mg tablets per week.

          -  Able to swallow oral medications

          -  Laboratory: WBC ≥ 4.0 x 103/mcL, platelets ≥ 100,000/mcL and hemoglobin > 11.0 g/dL.
             Serum bilirubin ≤ 2.0 mg/dL and AST (SGOT) or ALT(SGPT) ≤ 2 x IULN. Serum creatinine ≤
             1.5 x IULN

          -  Zubrod PS 0-1, 18 years of age or older

          -  Will not participate in any other clinical trial for the treatment or prevention of
             cancer unless off protocol treatment, on follow-up phase only

          -  Offered opportunity to participate in blood specimen banking

        Exclusion Criteria:

          -  History of colon resection > 40 cm

          -  Mid-low rectal cancer

          -  Recurrent or metastatic disease

          -  High cardiovascular risk; Uncontrolled hypertension

          -  Planned radiation therapy or additional chemotherapy

          -  Documented history of gastric/duodenal ulcer within last 12 months and/or current
             treatment or active symptoms of gastric/duodenal ulcer

          -  Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal
             cancer, or inflammatory bowel disease

          -  ≥ 30 dB uncorrectable hearing loss for age of any of the five tested frequencies on
             prestudy audiogram

          -  Known hypersensitivity to sulindac or excipient byproducts. Previous asthma,
             urticaria, or allergic-type reaction to aspirin or other NSAIDs

          -  Significant medical or psychiatric condition that would preclude study completion (8
             years)

          -  No other prior malignancy except adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease-free for > 5 years

          -  Pregnant or nursing women. Women/men of reproductive potential must agree to use
             effective contraception